Embecta Corp. faces securities class action lawsuit

Embecta Corp. (NASDAQ: EMBC) is facing a securities class action lawsuit seeking to represent investors who purchased or acquired Embecta common stock between November 25, 2025, and May 4, 2026. The action follows the company's second-quarter earnings report, which appeared to contradict prior statements, leading to a significant stock sell-off and analyst scrutiny.

The lawsuit centers on Embecta's repeated assurances regarding the stability of its pen needle business and its financial projections. On February 5, 2026, the company reiterated its 2026 adjusted earnings per share guidance of $2.80 to $3.00, describing its pen needle business as "incredibly resolute." The company also maintained its dividend as part of its capital allocation plans.

Plaintiffs allege that Embecta's assurances and guidance were misleading because the company knew or recklessly disregarded that weaknesses in the pen needle market were likely to significantly disrupt its annual forecast and Q2 results. On May 5, 2026, Embecta reported Q2 2026 adjusted EPS of $0.27, a decline of approximately 61% sequentially and year-over-year.

Consequently, Embecta slashed its 2026 adjusted EPS guidance to $1.55-$1.75 and reduced its dividend by 93%. Following this news, Embecta's stock price plummeted. One prominent analyst highlighted management's need to "rebuild investor credibility on commercial execution and the profitability outlook."